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ABSTRACT
Premature termination of translation due to nonse-
nse mutations is a frequent cause of inherited
diseases. Therefore, many efforts were invested in
the development of strategies or compounds to
selectively suppress this default. Selenoproteins are
interesting candidates considering the idiosyncrasy
of the amino acid selenocysteine (Sec) insertion
mechanism. Here, we focused our studies on
SEPN1, a selenoprotein gene whose mutations
entail genetic disorders resulting in different forms
of muscular diseases. Selective correction of a non-
sense mutation at the Sec codon (UGA to UAA) was
undertaken with a corrector tRNA
Sec that was
engineered to harbor a compensatory mutation in
the anticodon. We demonstrated that its expression
restored synthesis of a full-length selenoprotein N
both in HeLa cells and in skin fibroblasts from
a patient carrying the mutated Sec codon.
Readthrough of the UAA codon was effectively
dependent on the Sec insertion machinery, therefore
being highly selective for this gene and unlikely to
generate off-target effects. In addition, we observed
that expression of the corrector tRNA
Sec stabilized
the mutated SEPN1 transcript that was otherwise
more subject to degradation. In conclusion, our data
provide interesting evidence that premature termi-
nation of translation due to nonsense mutations is
amenable to correction, in the context of the
specialized selenoprotein synthesis mechanism.
INTRODUCTION
Selenoproteins belong to a family of proteins that contain
a covalently bound atom of selenium as part of the amino
acid selenocysteine. Selenocysteine (Sec) is co-translation-
ally incorporated into proteins, and in all selenoenzymes,
studied so far, it was shown that Sec is directly involved
in the catalytic mechanism. The presence of the selenol
group confers an important increase in reactivity versus a
cysteine thiol (1,2). Insertion of the Sec residue into the
polypeptide chain is a highly speciﬁc event which involves
several exceptions to the canonical translational rules
(3,4). First, Sec is encoded by UGA, a codon that would
be recognized as a stop in a diﬀerent context. In
eukaryotes, reprogrammation of the UGA Sec is achieved
by an RNA structure, the SECIS element (SElenoCysteine
Insertion Sequence), located in the 30UTR of selenopro-
tein mRNAs. This motif is speciﬁcally recognized by the
RNA-binding protein SBP2, which in turn recruits the
complex formed by the specialized elongation factor
EFSec and the charged selenocysteine tRNA
Sec (5). In
prokaryotes, it was shown that the tRNA
Sec harbors
several determinants which prevent its recognition by the
general translation elongation factor EF-Tu but allow
speciﬁc binding of SelB, the elongation factor dedicated to
Sec incorporation. In addition, synthesis of the Sec residue
occurs directly on the tRNA
Sec which is initially charged
with serine by the seryl-tRNA synthetase. Conversion of
the seryl- to selenocysteyl-residue is subject to multiple
enzymatic steps in eukaryotes (6). How this complex
machinery interacts with the ribosome to dictate
speciﬁc incorporation of the selenocysteine residue in
response to the UGA codon remains to be elucidated.
Present address:
M. Rederstorff, Innsbruck Biocenter, Division of Genomics and RNomics, Innsbruck Medical University, Austria.
The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
*To whom correspondence should be addressed. Tel: 33 3 88 41 70 80; Fax: 33 3 88 60 22 18; Email: a.lescure@ibmc.u-strasbg.fr
 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.To date, 25 selenoproteins have been identiﬁed in
humans. Among them is Selenoprotein N (SePN) (7),
the ﬁrst selenium-containing protein which was associated
to a genetic disorder (8). Mutations in the SEPN1 gene
cause diﬀerent forms of autosomal recessive muscle
disorders: congenital muscular dystrophy with spinal
rigidity (RSMD1) (8); multiminicore myopathy (MmD)
(9); desmin-related myopathy with Mallory body-like
inclusions (MB-DRM) (10); and congenital ﬁber-type
disproportion myopathy (CFTD) (11). Although the
histopathological descriptions of these diﬀerent disorders
are distinct, clinical reevaluation of patients with these
diagnoses showed that they share identical clinical
features characterized by early weakness of axial muscles,
development of spinal rigidity and scoliosis as well as
severe respiratory insuﬃciency. These phenotypes are now
grouped under the generic term of SEPN1-related
myopathy. The molecular function of SePN is still
unknown, but it was characterized as a glycoprotein of
the endoplasmic reticulum. In addition, SePN was shown
to be highly expressed in proliferative muscle precursor
cells (12). In zebraﬁsh, analysis of the SEPN1 gene-
expression pattern during early development revealed
high expression in the somites and the notochord, two
tissue precursors for the diﬀerentiation of skeletal
muscles. Moreover, knockdown of SEPN1 expression in
developing zebraﬁsh embryos causes disorganization of
the muscle architecture and reduced motility (13).
Numerous mutations, scattered all over the SEPN1
gene, have now been identiﬁed in patients (14). Most of
them are nonsense mutations and deletions, likely to
induce a loss of function. Recently, we characterized a
pathological mutation within the SECIS motif in the
30UTR of SEPN1 mRNA, abolishing the binding of SBP2
and therefore preventing synthesis of a full-length
active SePN protein (15). With the detailed knowledge
of the molecular mechanisms and dysfunctions underlying
genetic diseases, correction of genetic defects may now
be envisioned. Over the last decade or so, a lot of eﬀorts
have been targeted towards the development of cell- or
gene-based therapies. However, these approaches present
a number of hurdles especially for muscular diseases,
mainly due to the size of the genes considered and the
selectivity of the target tissue (16). Here, we propose a
mutation-speciﬁc correction strategy based on the use of
a modiﬁed tRNA
Sec. The presence of this tRNA will force
recognition of a mutated Sec codon in a RSMD1 patient
with a homozygous point mutation at the Sec codon
(c.G1385A) (8), converting UGA to UAA. Indeed, it was
previously reported that the UGA codon is not strictly
required for Sec incorporation into proteins, and that
other stop codons could be used as well, provided that
the codon/anticodon complementarity is maintained (17).
In addition, both the seryl-tRNA synthetase and the
machinery which converts serine to selenocysteine were
shown to act independently of the anticodon sequence
(18,19). Therefore, it was a reasonable assumption that
the expression of a corrector tRNA
Sec would rescue
expression of the mutated UAA SEPN1 gene. We
engineered a mutant tRNA
Sec gene carrying a point
mutation in the anticodon, thereby restoring the base-pair
complementarity with the SEPN1 mutated codon.
We demonstrated, both in HeLa cells and in patient-
derived primary ﬁbroblasts, that the corrector tRNA
Sec
gene indeed allowed read-through of the UAA stop
codon, thus enabling synthesis of the full-length SePN
protein. In addition, the speciﬁcities of the molecular
mechanisms of the selenoprotein synthesis machinery
constitute an invaluable asset rendering this strategy
feasible and avoiding cross-eﬀects on the normal transla-
tion of other cellular proteins.
MATERIALS AND METHODS
Cloning and plasmid constructs
The gene encoding the human tRNA
Sec was PCR
ampliﬁed from human genomic DNA. The resulting
678bp fragment spans positions  420 to +257 relative
to the 50 end of the tRNA
Sec and incorporates all the
upstream promoter and downstream regions required
for eﬃcient transcription and maturation (20). A SalI
restriction site was introduced at both extremities of the
PCR fragment for cloning into the pSK( ) vector. This
construct was named tRNA
Secwt. Mutation of the TCA
anticodon sequence to TtA was engineered by site-directed
mutagenesis. The cDNA-encoding SePN cloned into the
eukaryotic expression vector pXJ41 and previously
described as pXJSelN6 in Ref. (12) was used as the
SePNwt construct. Mutations of the UGA selenocysteine
codon to UaA stop or gGA glycine, were introduced into
the SePNwt construct by site-directed mutagenesis.
Deletion of the SECIS element in SePNwt, SePNuaa
and SePNgga was obtained by removing 1609bp of the
30UTR sequence; downstream of the unique Nhe1 site
located 200bp upstream of the SECIS element.
Cell cultureand transfection
HeLa cells (ATCC) were cultured in DMEM, supplemen-
ted with 10% fetal calf serum, 20 U/ml streptomycin
and penicillin at 378C with 5% CO2. At 70–80%
conﬂuence, cells were transfected by calcium phosphate
precipitation with 1mg of the diﬀerent pXJ-SePN con-
structs and cotransfected with 1mg of the diﬀerent pSK-
tRNA
Sec variants, as described in the text. After 16h
incubation, the medium was changed and the cells were
further grown for 20h or deﬁned periods as indicated
in the ﬁgures. Primary ﬁbroblasts were obtained from a
skin biopsy of patient 14961 (8) performed at the age of
13. Cells were grown as previously described (12).
Following detachment using trypsin-EDTA, 5 10
5 cells
(about 60–70% conﬂuent) were transfected with 2mgo f
tRNA
Secwt or tRNA
Secuua expression vectors, using the
Normal Human Dermal Fibroblast Nucleofector
TM kit
(NHDF-Adult, Amaxa) according to the manufacturer
recommendations (program U-23). Re-expression
of SePN was investigated 24, 48, 72 and 96h post-
nucleofection. As a negative control, cells were nucleo-
fected in the absence of plasmid DNA. As a control for
transfection eﬃciency, a GFP reporter plasmid was
co-transfected with the tRNA
Sec constructs. GFP ﬂuores-
cence was monitored 24–96h post-transfection.
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Transfected HeLa cells were lyzed by the freeze–thaw
procedure in 100mM Tris–HCl, pH 8. The lysate was
centrifuged at 13000 r.p.m. for 20min, and the SePN
protein was extracted from the membranous pellet. The
pellet was resuspended in 25–50ml extraction buﬀer
(50mM Tris–HCl pH7.5, 200mM NaCl, 1.25mM CaCl2,
1mM MgCl2, 1% Triton X-100) and incubated for 20min
at48C.Aftercentrifugationfor15minat13000r.p.m.,5mg
of protein extract were subjected to SDS–PAGE and
transferred to PVDF membranes. A 1/2000 dilution of the
primary anti-SePN polyclonal antibody, Ac168, was used
in a 3% milk, 0.1% Tween 20, PBS solution. Total proteins
from conﬂuent human ﬁbroblasts were obtained as
previously described (15). Twenty microgram of total
proteins were fractionated and transferred to PVDF
membranes which were hybridized with polyclonal anti-
body R139 against the C-terminus of the protein (dilution
1/100). For loading control, blots were subsequently
stained with a monoclonal antibody against b-actin
(Sigma, dilution 1/2000). HRP-conjugated secondary
antibodies were used at a dilution of 1/1000.
Detection ofthe different tRNA
Sec entities by chain
termination primer extension
A total RNA fraction was prepared from transfected
HeLa cells by Tri Reagent
TM (Euromedex) extraction.
A dideoxyoligonucleotide complementary to tRNA
Sec
sequence was
32P-labeled at its 50 end using T4 poly-
nucleotide kinase. Four microgram of total cellular RNAs
were hybridized to 2.10
5c.p.m. of the radioactive probe
in a total volume of 8ml, by heating at 908C for 2min,
followed by immediate freezing in dry ice. Next, 2mlo f
5  RT buﬀer (250mM Tris–HCl pH 8.3, 200mM KCl,
40mM MgCl2, 5mM DTT) was added directly on top
of the frozen reaction medium, and incubated at room
temperature for 3min. Primer extension was performed in
a1 5 ml reaction in 1  RT buﬀer, containing 2U AMV
Reverse Transcriptase (QBiogen). To monitor the
tRNA
Secwt/tRNA
Secuua ratio, a nucleotide mix contain-
ing 0.5mM dATP/dTTP and 0.25mM ddGTP, was
included. As a control, the total amount of tRNA
Sec was
measured by adding 0.5mM dATP/dTTP/dGTP and
0.25mM ddCTP. Extension was performed for 30min at
428C. The reaction mix was then precipitated, the pellet
was resuspended in 6ml TE plus 4ml sequencing dye mix.
The reaction product was heated for 3min at 908C and
fractionated on a 10% denaturing polyacrylamide gel.
RNA extraction and quantitative RT-PCR
Total RNAs were extracted from cultured skin ﬁbroblasts
with Trizol as previously described (15). First strand
cDNA was prepared in a 20ml ﬁnal volume reaction
from 1mg of total RNA using oligo(dT)18 and Superscript
II RT as recommended by the manufacturer (InVitrogen).
Quantitative real-time PCR was carried out by amplifying
a 290bp fragment spanning exons 9–11. The housekeeping
gene HPRT was used as a reference on the Light Cycler
real-time PCR machine using SyBR Green.
RESULTS
Incidenceof two pathological mutations inthe
selenocysteine codonon SEPN1 expression
Several mutations were identiﬁed in the SEPN1 gene in
patients with SEPN1-related myopathy. Many of them
are clustered in the vicinity of the putative catalytic site,
as deduced from the position of the selenocysteine (Sec)
residue. Among them, two diﬀerent point mutations aﬀect
the Sec codon directly. The ﬁrst one consists in a UGA
to UaA change [c.G1385A, p.U462X; (8)], introducing a
stop codon which cannot be decoded by the Sec insertion
machinery (Figure 1A). The second one converts the UGA
Sec to a gGA glycine. To test the eﬀects of these two
mutations on SEPN1 expression, both nucleotide changes
were introduced into the SEPN1 construct and the
cDNAs were transiently expressed into HeLa cells. The
translation products were compared to the wild-type
selenoprotein N, SePNwt (Figure 1B, lane 2) or to that
arising from a construct lacking the SECIS element,
SePNSECIS. In the absence of the SECIS element, the
UGA Sec codon was not decoded, yielding to the synthesis
of a truncated SePN protein (Figure 1B, lane 3). As
predicted from the coding capacity of the two mutations,
expression of SePNgga produced a full-length protein
whereas the mutated codon in SePNuaa was recognized
as a stop (Figure 1B, lanes 4 and 6). In addition,
translation of the full-length protein from SePNgga was
no longer dependent on the presence of the SECIS element
(Figure 1B, lane 5). The SePNgga product accumulated at
a higher level than SePNwt, which is representative of the
low eﬃciency of selenocysteine insertion compared to
other amino acids. Since the SePNgga protein is highly
expressed, and because the UGA to gGA mutation leads
to a muscle phenotype in patients, one should deduce that
substitution of glycine for selenocysteine is highly
deleterious to SePN catalytic activity. As this activity is
presently unknown, it could not be assayed in vitro. On the
other hand, the expression level of the short SePNuaa
product was lower than that obtained with the UGA-
containing SePNSECIS construct. This may indicate
that the UGA Sec to UaA mutation destabilized the SePN
mRNA. Finally, it is interesting to note that, in both
SePNggaSECIS and SePNuaaSECIS, removal of the
30 UTR domain which contains the SECIS motif, led to
increased expression levels (Figure 1B, compare lanes 4, 5
and 6, 7). Therefore, it is likely that in addition to the
SECIS, other RNA regulatory motifs such as RNA
destabilizing elements or translation inhibitory sequences,
were removed.
Acorrector tRNA
Sec transgene rescuesexpression
ofaSEPN1 mutant
Next, we investigated the possibility of correcting the
SePNuaa mutation by expressing a tRNA
Sec gene
harboring a compensatory mutation in the anticodon
sequence, tRNA
Secuua. In HeLa cells, co-expression of the
wild-type tRNA
Sec, tRNA
Secwt, had no major impact
either on SePNwt or SePNuaa synthesis (Figure 1, com-
pare lanes 9, 10 and 11, 12). However, co-expression of the
Nucleic Acids Research,2008, Vol. 36,No. 1 239SePNuaa mutant with the cognate corrector tRNA
Secuua
produced a band of the size expected for the full-length
SePN protein (Figure 1, lane 13). Interestingly, correction
of the SePNuaa mutant by tRNA
Secuua was obtained only
in the presence of the SECIS element (Figure 1, compare
lanes 13 and 15), demonstrating that the read-through of
the UAA codon by tRNA
Secuua was dependent on the
selenocysteine insertion machinery. This observation
strongly suggests that a selenocysteine residue was
incorporated at the expected position. Additional experi-
ments showed that expression of tRNA
Secuua did not alter
synthesis of either SePNwt or SePNgga, verifying the
speciﬁcity of the correction for the mutated UAA
selenocysteine codon (Supplementary Figure 1).
Accumulation of thecorrector tRNA
Secuua in HeLacells
allowshighexpressionofthefull-lengthmutantSePNprotein
In the previous experiments, the amount of full-length
SePN recovered by co-expressing the SePNuaa mutant
and the corrector tRNA
Secuua was rather low compared
to the wild-type protein. We hypothesized that this
might reﬂect a delay in the accumulation of tRNA
Secuua
within the intracellular tRNA
Sec pool, therefore aﬀecting
the translation capacity of the reprogrammed UAA
codon. To test this, we performed a time-course experi-
ment of the expression of SePNwt or SePNuaa in the
presence of the corresponding tRNA
Secwt or tRNA
Secuua
(Figure 2A). Both in the presence or absence of
tRNA
Secwt, SePNwt expression was already maximal
22h post-transfection. In contrast, the highest expression
level of SePNuaa with tRNA
Secuua was reached only
10h later, at 32h. At 72h, the SePN level decreased in
all cases, likely corresponding to the loss of the expression
plasmids.
In parallel, the level of the diﬀerent tRNA
Sec species in
the transfected cells was evaluated by chain termination
primer extension. An oligonucleotide, complementary
to the variable arm and part of the anticodon stem of
both tRNA
Secwt and tRNA
Secuua (Figure 2B, solid red
line), was used as the primer for hybridization on total
cellular RNAs. Primer extension was performed in the
presence of ddGTP. In this case, extension will stop at the
ﬁrst C residue, which is encountered in the anticodon
for tRNA
Secwt or 3nt toward 50 in tRNA
Secuua (red
dotted line in Figure 2B). Hence, the diﬀerential tRNA
variant-speciﬁc extension products were used to monitor
the level of both tRNA
Secwt and tRNA
Secuua in the cells
at diﬀerent time points (Figure 2C). As an internal
control, the total tRNA
Sec level was measured by per-
forming primer extension under conditions in which the
extension proceeds up to the ﬁrst G residue corresponding
to the last G–C base pair closing the anticodon loop, a
position common to both tRNA
Secwt and tRNA
Secuua.
Transfection of the tRNA
Secwt expression vector in HeLa
cells did not lead to an increase in the tRNA
Sec level which
remained stable over time (Figure 2C, compare left and
central panels). This might reﬂect the saturation of the
tRNA-processing machinery which regulates the intracel-
lular pool of each tRNA species. Similar results were
previously reported by Buvoli et al. (21). In contrast, the
corrector tRNA
Secuua clearly accumulated within the
tRNA
Sec pool in a manner paralleling the accumulation of
the SePN protein arising from the SePNuaa construct
(Figure 2A and C, compare right panels). This observa-
tion further reinforced the criteria of a speciﬁc correction
of SePNuaa by the recombinant tRNA
Secuaa. Because the
primer extension was conducted in the presence of an
excess of primer, the proﬁles obtained were representative
of each tRNA entity level. Noteworthy, the tRNA
Secuua
mutant was eﬃciently expressed and accumulated in the
transfected cells to a level equivalent to the endogenous
tRNA
Sec.
Transient expression ofthe corrector tRNA
Secuua inpatient
fibroblastsrestoredexpressionofthefull-lengthSePNprotein
Another aspect of this study was to assess the ability of
the corrector tRNA
Secuua to allow expression of the
full-length SePN from the mutated SEPN1uaa gene in
human primary ﬁbroblasts derived from a RSMD1
patient. Western blot analysis using a C-terminal
mock
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SePNDSECIS
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SePNwt + tRNA Sec wt
SePNuaa
SePNuaa + tRNA Sec wt
SePNuaa + tRNA Sec uua
SePNuaaDSECIS
SePNuaa DSECIS + tRNA Sec uua
B
A
UGA
UaA
Sec
stop
SECIS motif
Gly
gGA
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Figure 1. Expression of two SEPN1 mutations causing rigid spine
muscular dystrophy. Rescue of a UGA Sec to UAA nonsense mutation
by a corrector tRNA
Sec in HeLa cells. (A) The presence of a SECIS
RNA motif in the 30UTR of selenoprotein mRNAs promotes insertion
of a selenocysteine (Sec) residue in response to a UGA codon.
Mutation of this triplet to UAA prevents recognition by the
selenocysteine insertion machinery, inducing a premature stop of
translation and synthesis of a truncated polypeptide. Proteins arising
from translation of the wild-type UGA or mutant UAA mRNAs are
schematized as cylinders. (B) SePN expression from transfected HeLa
cells was analyzed by western blot using a SePN polyclonal antibody
(Ac168). Lanes 1–7: Constructs carrying the UGA Sec to glycine
(GGA, SePNgga) or nonsense (UAA, SePNuaa) mutations were
transfected and the expression proﬁles were compared to the wild
type (SePNwt). SECIS lacking constructs (SECIS) were also tested.
The upper band corresponds to the full-size SePN protein (SePN). The
lower band, which is obtained with SePNuaa or with SECIS-lacking
constructs, corresponds to the premature stop of translation at the
UGA/UAA Sec position (Lanes 2, 3, 6, 7, 9–15; SePN
 ). Co-expression
of the SePNuaa mutant with the corrector tRNA
Secuua (lane 13), but
not with tRNA
Secwt (lane 12), restored synthesis of the full-size SePN
protein. Rescue of the SePNuaa mutant is speciﬁc of the selenocysteine
insertion machinery since it was dependent on the presence of the
SECIS element (lane 15).
240 Nucleic Acids Research, 2008, Vol. 36, No. 1polyclonal antibody showed that no band could be
detected in the total protein extract from the patient
ﬁbroblast, as opposed to the  70kDa band obtained from
control ﬁbroblasts (Figure 3B, compare lanes 1 and 2).
Interestingly, no shorter product could be detected in the
patient ﬁbroblasts. Next, the primary ﬁbroblasts were
transiently transfected with the plasmid expressing either
the tRNA
Secwt or the tRNA
Secuua, using the
Nucleofector (Amaxa). Transfection eﬃciency was mon-
itored by co-transfection of a GFP reporter gene. Both
tRNA
Secwt and tRNA
Secuua expression vectors were
transfected with a similar eﬃciency of  30%
(Figure 3A). Noticeably, a band corresponding to SePN
started to appear in the patient ﬁbroblasts transfected
with the corrector tRNA
Secuua, as soon as 24h post-
transfection (Figure 3B, lanes 11–14). This correction was
speciﬁc to tRNA
Secuua since no equivalent band was
observed in the mock-transfected mutant ﬁbroblasts
(Figure 3B, lane 10) or upon transfection of the
tRNA
Secwt (Figure 3B, lanes 4–7). The intensity of this
band increased with time as expected from the previous
experiments. In parallel, we analyzed the SEPN1 mRNA
level by quantitative RT-PCR. In the RSMD1 mutant
ﬁbroblasts, this level was  25% of the control. This result
demonstrated that mutation of the UGA Sec codon to
UAA, which introduces a premature stop of translation,
led to an increased turnover of the SEPN1 transcript.
Strikingly, expression of the corrector tRNA
Secuua
induced stabilization of the mutated transcript which
rose up to  60% of a control individual, 96h after
transfection. Expression of tRNA
Secwt had no inﬂuence
under similar conditions (Figure 4). Therefore, expression
of the corrector tRNA
Secuua had a dual role at the post-
transcriptional level on the expression of the mutated
SEPN1 gene, (i) by stabilizing the transcript and (ii) by
allowing insertion of the selenocysteine residue.
DISCUSSION
In this article we report the correction, by a recombinant
tRNA
Sec gene, of a nonsense UAA mutation in the
selenoprotein N gene. This private mutation arose at the
position of the selenocysteine UGA codon and caused at
the homozygous state a congenital muscular dystrophy,
RSMD1, in a patient aﬀected by early axial weakness,
rigid spine and respiratory insuﬃciency (8). We showed
that correction of this mutation can be eﬃciently achieved
provided that codon/anticodon complementarity is
restored. First, we demonstrated in HeLa cells that the
corrector tRNA
Secuaa was readily expressed and accumu-
lated to levels comparable to that of the endogenous wild-
type tRNA
Sec. The corrector tRNA
Secuua was active in
the read-through of the nonsense mutation since it allowed
speciﬁc expression of a full-length SePN protein in a
SECIS-dependent manner. Second, expression of the
corrector tRNA
Secuaa in skin ﬁbroblasts obtained from
the patient with the mutant UAA codon, restored
synthesis of the full-length SePN protein by providing
both recoding of the mutated codon and stabilization of
the transcript. Actually, mutation of the UGA
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Figure 2. Time-course expression of the various SePN or tRNA
Sec
constructs in transfected HeLa cells. (A) The accumulation of the wild-
type SePN (SePNwt) or its mutated form (SePNuaa) co-expressed with
the cognate tRNAs
Sec (tRNA
Secwt or tRNA
Secuua) were analyzed by
western blot analysis at diﬀerent time points (shown above the panels).
SePNwt saturated at 22h, whereas the SePNuaa mutant accumulated
up to 32h. Migration of the full size and truncated forms of SEPN are
indicated (SePN and SePN
 , respectively). (B and C) In parallel, the
level of the diﬀerent tRNAs
Sec was analyzed by chain termination
primer extension. Because of the absence of a C residue in the
anticodon sequence of the tRNA
Secuua, primer extension performed in
the presence of ddGTP proceeded up to position +7 for tRNA
Secuua
(numbering starting from the 30 end of the primer), while it stopped at
position +4 for tRNA
Secwt (B and top C panels). The total amount of
tRNA
Sec (Tot tRNA
Sec) was estimated using ddCTP as the termination
nucleotide, giving rise to a speciﬁc band at +8 with both the
tRNA
Secwt and tRNA
Secuua (B and lower C panels). Accumulation
of both tRNA
Secwt and tRNA
Secuua was analyzed at diﬀerent time
points and compared to the endogenous pool of cellular tRNA
Sec
(mock transfected). In the control (left columns), primer extension was
performed under similar conditions, but omitting cellular RNAs. This
control was used to visualize the migration of the primer ( ) and to
ascertain the absence of unspeciﬁc extension products. The solid red
line (panel B) represents the 30 end of the primer. The dotted red and
gray lines show the extension products obtained in ddGTP and ddCTP-
containing primer extension experiments, respectively.
Nucleic Acids Research,2008, Vol. 36,No. 1 241selenocysteine to a UAA stop codon resulted in a lower
accumulation of the SEPN1 mRNA in the patient
ﬁbroblasts. We previously reported a similar observation
for a mutation in the central core of the SECIS element.
This mutation, observed in a patient with the RSMD1
phenotype, prevented SBP2 from binding to the SECIS
element. As a result, the UGA Sec codon was recognized
as a premature stop codon, inducing destabilization of the
transcript (15). The presence of nonsense mutations within
mRNA-coding regions was demonstrated to promote
mRNA degradation by nonsense-mediated mRNA decay
(NMD), a mechanism dedicated to mRNA quality control
(22). Our results suggest that read-through of the nonsense
codon following expression of the corrector tRNA
Sec,
allowed the mutated SEPN1 mRNA to escape the NMD
pathway, increasing the level of this mRNA in the patient
ﬁbroblasts and therefore stimulating expression of the full-
length SePN protein. Phylogenetic analysis by others,
validated by mutagenesis experiments, identiﬁed the
presence of a conserved cis-acting selenocysteine codon
redeﬁnition element, also termed SRE, downstream of the
UGA Sec codon in SEPN1 (23,24). This element,
consisting in a stem-loop structure, was shown to
stimulate read-through of both UGA and UAG codons.
Here, our data reinforce the notion that the activity of the
SRE in the SEPN1 mRNA is not dependent on the
identity of the triplet recoding selenocysteine, since UAA
was eﬃciently decoded by the corrector tRNA
Secuua.
Forced read-through of premature termination codons
through tRNA suppression or treatment by aminoglyco-
sides has been reported as a potential therapeutic
approach to restore translation of mRNAs containing
nonsense mutations, which cause a large number of
human diseases (21,25–27). Recently, a new drug issued
from high-throughput screens, PTC124, was characterized
for its ability to selectively induce read-through of
premature termination codons (28). The success of a
therapeutic suppression strategy relies on the possibility of
removing the translation blockage caused by nonsense
mutations without aﬀecting termination at genuine stop
codons. Indeed, over-expression of suppressor tRNA
genes was shown to have toxic eﬀects on cell metabolism
in diﬀerent systems (29–31). Our correction strategy
presents several advantages derived from the speciﬁcity
of the selenocysteine insertion mechanism. First, the
tRNA
Sec is not recognized by the general translation
elongation factor EF1A. Rather, it is recruited only and
speciﬁcally by the specialized elongation factor EFSec to
decode UGA Sec codons in selenoprotein mRNAs.
Therefore, the corrector tRNA
Sec will not suppress the
genuine UAA stop codons in other cellular mRNAs and is
expected to have less oﬀ-target eﬀects than a traditional
tRNA suppressor strategy. Generally, eﬃcient suppres-
sion of nonsense mutations using tRNA suppressors
requires high expression from multicopy genes (21).
In contrast to other tRNAs, tRNA
Sec is transcribed
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Figure 3. Expression of the corrector, but not wild-type tRNA
Sec,
rescues SePN expression in ﬁbroblasts from a RSMD1 patient carrying
the SEPN1uaa mutation. Both the wild-type and corrector tRNA
Sec
expression vectors were transfected into cultured ﬁbroblasts from a
patient carrying the SEPN1uaa mutation. (A) The eﬃciency of
transfection was assayed by co-expression of a GFP reporter protein.
Transfected cells were visualized using ﬂuorescence microscopy
(left panels). The transfection eﬃciency of both tRNAs was similar.
(B) Expression of SePN was determined by western blot analysis in
transfected ﬁbroblasts at 24h (lanes 4 and 11), 48h (lanes 5 and 12),
72h (lanes 6 and 13) or 96h (lanes 7 and 14) and compared to mock
transfected at 96h (lanes 3 and 10), untransfected cells (lanes 2 and 8)
or control ﬁbroblasts (lanes 1 and 7). As shown above each panel,
either the wild-type (lanes 1–7) or corrector tRNAs
Sec constructs (lanes
8–14) were transfected. b-Actin was used as a control for equivalent
loading (lower panels).
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Figure 4. Stability of the SEPN1uaa transcript under pathological or
corrected conditions. SEPN1 mRNA levels were measured by
quantitative PCR from nucleofected ﬁbroblasts of a RSMD1 patient
transfected either with tRNA
Secwt or tRNA
Secuua expression vectors.
Scores were normalized to a HPRT control gene and levels were
expressed as a percentage of the wild-type SEPN1 mRNA in ﬁbroblasts
from a control individual. The SEPN1uaa transcript was destablized,
but transfection of the corrector tRNA
Secuua restored  60% of the
SEPN1 wt mRNA level.
242 Nucleic Acids Research, 2008, Vol. 36, No. 1from a single copy gene (tsrp, 32), using a peculiar
promoter organization corresponding to a combination of
internal and external RNA polymerase III promoter and
activator elements yielding high transcription levels
(33,34). Therefore, high representativity of the corrector
tRNA
Secuua within the pool of wild-type tRNA
Sec can
easily be obtained in transfected cells, as veriﬁed in our
experiments.
One of the major hurdles in gene therapy is the ability to
eﬃciently and safely deliver the therapeutic gene via a
systemic route (16). For this purpose, both viral and non-
viral vectors have been developed. A major limitation of
viral vectors such as adeno-associated viruses (AAV), is
their relatively low cloning capacity. For non-viral
vectors, increasing plasmid size was shown to have a
dramatic eﬀect on transfection eﬃciency as well (35). In
this respect, our strategy presents another asset in that the
tRNA
Sec transcription unit was extensively characterized
and shown to harbor a compact organization with the
entire gene residing in a 680bp DNA fragment (20).
Because of this small size, tRNA
Sec is readily amenable to
all vectors. Of paramount consideration for gene therapy
is the need to obtain high expression of the recombinant
gene in the target tissue and to avoid ectopic expression.
Because tRNA genes are ubiquitously expressed and their
product eﬃciently matured, high levels of corrector
tRNA
Sec can be obtained without any accessory factors
in all cell lines or terminally diﬀerentiated tissues,
including muscle cells. This is not necessarily the case
for a selenoprotein-coding gene whose expression might
be regulated both at the transcriptional and post-
transcriptional levels in a tissue-speciﬁc manner (36).
Consequently, the correction strategy by a recombinant
tRNA
Sec presents several advantages versus a more direct
expression of a wild-type SEPN1 gene: ﬁrst the size of the
SEPN1 gene makes it much more diﬃcult to handle with
currently available vectors, and second its expression is
more complicated to control because of sophisticated
regulations. In addition, over-expression through plasmid
or viral vectors carrying a normal copy of the SEPN1 gene
is likely to result in the production of truncated proteins,
due to partial recognition of the UGA Sec codon as a
stop. Indeed, the eﬃciency of Sec insertion into seleno-
proteins is rather low (37,38) and the components of this
machinery may become rapidly saturated upon transfec-
tion of high amounts of the SEPN1 gene.
Taken together, our results demonstrate the eﬃciency
and advantages of a corrector tRNA
Sec-based strategy to
restore incorporation of a selenocysteine residue and
therefore to promote translation of the full-length
selenoprotein N. This mutation-speciﬁc approach consti-
tutes an interesting alternative to conventional gene-
therapy strategies in the highly speciﬁc context of
selenoproteins.
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